- Home
- DSS vs PPBT Comparison
DSS vs PPBT Comparison
Compare DSS & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSS
- PPBT
- Stock Information
- Founded
- DSS 1984
- PPBT 2010
- Country
- DSS United States
- PPBT Israel
- Employees
- DSS N/A
- PPBT N/A
- Industry
- DSS Containers/Packaging
- PPBT Biotechnology: Pharmaceutical Preparations
- Sector
- DSS Consumer Discretionary
- PPBT Health Care
- Exchange
- DSS Nasdaq
- PPBT Nasdaq
- Market Cap
- DSS 7.3M
- PPBT 7.1M
- IPO Year
- DSS N/A
- PPBT N/A
- Fundamental
- Price
- DSS $0.87
- PPBT $2.65
- Analyst Decision
- DSS
- PPBT Strong Buy
- Analyst Count
- DSS 0
- PPBT 1
- Target Price
- DSS N/A
- PPBT $33.00
- AVG Volume (30 Days)
- DSS 82.9K
- PPBT 13.2K
- Earning Date
- DSS 03-31-2025
- PPBT 03-10-2025
- Dividend Yield
- DSS N/A
- PPBT N/A
- EPS Growth
- DSS N/A
- PPBT N/A
- EPS
- DSS N/A
- PPBT N/A
- Revenue
- DSS $19,097,000.00
- PPBT N/A
- Revenue This Year
- DSS N/A
- PPBT N/A
- Revenue Next Year
- DSS N/A
- PPBT N/A
- P/E Ratio
- DSS N/A
- PPBT N/A
- Revenue Growth
- DSS N/A
- PPBT N/A
- 52 Week Low
- DSS $0.77
- PPBT $2.00
- 52 Week High
- DSS $2.30
- PPBT $20.60
- Technical
- Relative Strength Index (RSI)
- DSS 43.96
- PPBT 40.91
- Support Level
- DSS $0.78
- PPBT $2.64
- Resistance Level
- DSS $1.03
- PPBT $2.93
- Average True Range (ATR)
- DSS 0.10
- PPBT 0.15
- MACD
- DSS -0.00
- PPBT 0.02
- Stochastic Oscillator
- DSS 25.97
- PPBT 2.46
About DSS DSS Inc.
DSS Inc is operating a business focused on Five operating segments Product Packaging, Biotechnology, Commercial Lending, Securities and Investment Management, and Direct Marketing. Currently operates five distinct business lines operate around the globe with primary operations in North America and Asia.
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.